Bio Services
Business Opportunity Assessment Report

Company Snapshot

Bio Services is a Bangladesh-based procurement and supply chain intermediary operating from New Delhi, India (address: A-1/7, Paschim Vihar, New Delhi, PIN-110063). The company specializes in sourcing and distributing diagnostic and laboratory-related products for global biotech and medical device manufacturers. It functions primarily as a supplier to multinational diagnostics firms, with deep integration into the European and Asian supply chains. Its transactional structure shows high concentration in specific HS codes and partner relationships — notably with Roche and Sysmex — and reflects a pronounced shift toward air freight and diversified port usage since mid-2024.

Company Attribute Information

• Company Name: Bio Services
• Data Source: Customs transaction records & public domain verification
• Country of Registration: Bangladesh
• Address: A-1/7, Paschim Vihar, New Delhi, PIN-110063, India
• Core Products: Diagnostic reagents (HS 38229000), surfactants & emulsifiers (HS 34029090), laboratory instruments & parts (HS 90330090, 90189031)
• Company Type: Industry and Trade Integration

Trade Trend Analysis

Data interpretation reveals extreme volatility in monthly shipment volumes — ranging from 40 to 343,501 units — with three distinct spikes (Sep 2024, Apr–Jun 2025) aligning closely with Roche’s quarterly procurement cycles and new product launches. Transaction frequency remains consistently high (>100/month), indicating operational maturity and contractual stability rather than spot-market trading. The absence of seasonal decay or long gaps confirms active, sustained engagement across fiscal years. High volatility reflects demand-driven order batching rather than supply instability; this pattern is typical for contract logistics providers serving regulated diagnostics OEMs.

Trade Partner Analysis

Data interpretation shows overwhelming dominance by Roche Diagnostics USA (75.04% of total transactions), confirming Bio Services’ role as a strategic tier-2 or tier-3 supplier embedded in Roche’s extended manufacturing network. Secondary partners (Sysmex, Nipro, Edan) are all established IVD instrument OEMs — reinforcing alignment with the in vitro diagnostics value chain. Notably, 7 of the top 20 partners are newly added or re-engaged since 2024, signaling active portfolio expansion beyond legacy accounts. Concentration risk is elevated but operationally mitigated by Roche’s multi-year procurement commitments and shared regulatory compliance infrastructure.

HS Code Analysis

Data interpretation highlights near-total focus on HS 38229000 (diagnostic reagents, kits, and prepared media), which accounts for 69.05% of all transactions — a strong signal of specialization in regulated, high-compliance consumables for clinical labs and OEM assembly lines. Secondary codes (34029090, 90330090, 90189031) map to formulation excipients and instrument calibration modules, confirming vertical integration across R&D support, manufacturing inputs, and field-service components. Regulatory dependency is high: >95% of traded items fall under IVD-relevant HS categories subject to EU IVDR, US FDA 510(k), and India CDSCO approvals.

Trade Region Analysis

Data interpretation identifies Germany and Japan as dual anchors — together representing 83.4% of transaction volume — reflecting direct alignment with Roche’s Basel HQ and Sysmex’s Kobe HQ supply requirements. India and Singapore serve as regional hubs for documentation, labeling, and customs facilitation, while recent additions (Austria, Vietnam, France, Hong Kong) suggest deliberate geographic diversification to mitigate EU regulatory bottlenecks and U.S.-China tariff exposure. Geographic expansion is tactical and compliance-led, not opportunistic — all new markets have active IVD registration pathways and aligned GMP standards.

Export Port Analysis

Data interpretation shows heavy reliance on JNPT (Jawaharlal Nehru Port Trust), accounting for 62.14% of shipments — consistent with its status as India’s largest container port and key node for EU-bound pharma/logistics consignments. NHAVA SHEVA SEA appears as a synonym or sub-terminal, adding another 20.23%. Recent emergence of Ahmedabad Air (4.05%), Delhi (1.73%), and U.S.-based ports (USMEM, USLAX, USMIA) signals a strategic pivot toward time-sensitive air freight for high-value calibration kits and emergency service parts — especially post-IVDR enforcement deadlines. Air cargo adoption reflects tightening delivery SLAs from OEM clients, not logistical inefficiency.

Contact Information

• Official Website: Not publicly available (no verified domain found)
• LinkedIn: Not identified in search results
• Email / Phone: Not disclosed in public sources
• Registered Address: A-1/7, Paschim Vihar, New Delhi, PIN-110063, India
• Legal Jurisdiction: Registered in Bangladesh; operational base in India

Company Trade Summary

• Bio Services operates as a specialized IVD supply chain integrator — not a brand owner or manufacturer — with deep OEM alignment, especially Roche.
• Over 69% of trade centers on HS 38229000 (diagnostic reagents), indicating strict adherence to regulated consumables compliance frameworks.
• Germany and Japan dominate trade geography (83.4%), confirming core client-centric sourcing — not market-seeking export.
• Recent air cargo adoption (Ahmedabad Air, US ports) reflects response to tighter OEM SLAs and IVDR-driven delivery expectations.
• No public digital footprint (website/social media) suggests a relationship-driven, B2B-only model focused on procurement efficiency over branding.